Download Sample Report Now for highlights on market size, YOY growth rates, and other important statistics.
Segmentation Highlights:
Eczema Therapeutics Market Indication Outlook (Revenue, USD Billion, 2020-2025)
- Atopic dermatitis - size and forecast 2020-2025
- Contact dermatitis - size and forecast 2020-2025
- Other - size and forecast 2020-2025
The atomic dermatitis segment will have the largest share of the market. The segment is projected to grow at the fastest rate during the forecast period due to a strong pipeline landscape, with several promising product candidates in various stages of clinical development. In addition, the high prevalence of the indication, especially in the developed countries and urban areas will be contributing to the growth of the segment.
Eczema Therapeutics Market Geography Outlook (Revenue, USD Billion, 2020-2025)
- North America - size and forecast 2020-2025
- Europe - size and forecast 2020-2025
- Asia - size and forecast 2020-2025
- ROW - size and forecast 2020-2025
North America accounted for the largest share in 2020 among all regions in the global eczema therapeutics market. The market growth in the region can be attributed to factors such as early adoption of novel therapeutics, high awareness among the vastly susceptible cohort regarding the need for timely treatment, and the presence of established healthcare infrastructure in the region. In addition, the presence of favorable reimbursement policies, growing partnerships of key vendors with contract research organizations in emerging markets, and high healthcare expenditure will have an accelerating effect on the growth of the regional market.
Vendor Landscape
The global eczema therapeutics market is fragmented. A majority of the vendors in the market are currently engaged in the development and manufacture of therapeutic products for atopic dermatitis. Also, the market is competitive due to the presence of multiple companies manufacturing a range of similar generics. Key vendors are continuously expanding their business worldwide to maintain their dominance in the market over the coming years.
Technavio identifies the following as the dominant players in the market.
- AbbVie Inc.
- Alliance Pharma Plc
- Bausch Health Companies Inc.
- Bayer AG
- Eli Lilly and Co.
- Encore Dermatology Inc.
- LEO Pharma AS
- Pfizer Inc.
- Sanofi SA
- Viatris Inc.
For more highlights on the vendor landscape and other important segments, Download a Sample Report.
Key Growth Driver
The market is driven by the high prevalence of atopic dermatitis. The rise in risk factors such as exposure to allergens such as peanuts, pollen, or pet dander; skin irritants such as household cleaners, some fabrics, or soaps; stress; dry skin; and infections are increasing the prevalence of eczema globally. For instance, in the US, around 9-10 million children aged under 18 years are estimated to have atopic dermatitis. The presence of such a large patient pool is presenting significant growth opportunities for market players. Developing countries such as India and China are also expected to present promising market opportunities due to their large population and the increasing prevalence of atopic dermatitis in these regions. All these factors are expected to drive the growth of the global eczema therapeutics market during the forecast period.
Read Our Sample Report to identify other factors impacting the growth of the market.
Related Reports:
Eczema Therapeutics Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.2% |
Market growth 2021-2025 |
USD 4.29 billion |
Market structure |
Fragmented |
YoY growth (%) |
7.80 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 40% |
Key consumer countries |
US, Germany, UK, France, and Japan |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
AbbVie Inc., Alliance Pharma Plc , Bausch Health Companies Inc., Bayer AG, Eli Lilly and Co., Encore Dermatology Inc. , LEO Pharma AS, Pfizer Inc., Sanofi SA, and Viatris Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 01: Parent market
- Exhibit 02: Market characteristics
- Exhibit 03: Value chain analysis: Pharmaceuticals market
3 Market Sizing
- 3.1 Market definition
- Exhibit 05: Market segments
- 3.2 Market segment analysis
- 3.4 Market outlook: Forecast for 2020 - 2025
- Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
- Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
- 4.2 Bargaining power of buyers
- Exhibit 09: Bargaining power of buyers
- Exhibit 10: Bargaining power of suppliers
- 4.3 Bargaining power of suppliers
- Exhibit 11: Threat of new entrants
- 4.4 Threat of new entrants
- 4.5 Threat of substitutes
- Exhibit 12: Threat of substitutes
- 4.6 Threat of rivalry
- Exhibit 13: Threat of rivalry
- Exhibit 14: Market condition - Five forces 2020
5 Market Segmentation by Indication
- 5.2 Comparison by Indication
- Exhibit 17: Atopic dermatitis - Market size and forecast 2020-2025 ($ million)
- 5.3 Atopic dermatitis - Market size and forecast 2020-2025
- Exhibit 18: Atopic dermatitis - Year-over-year growth 2020-2025 (%)
- Exhibit 19: Contact dermatitis - Market size and forecast 2020-2025 ($ million)
- 5.4 Contact dermatitis - Market size and forecast 2020-2025
- Exhibit 20: Contact dermatitis - Year-over-year growth 2020-2025 (%)
- Exhibit 21: Other - Market size and forecast 2020-2025 ($ million)
- 5.5 Other - Market size and forecast 2020-2025
- Exhibit 22: Other - Year-over-year growth 2020-2025 (%)
- Exhibit 23: Market opportunity by Indication
- 5.6 Market opportunity by Indication
6 Customer landscape
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 26: Geographic comparison
- 7.2 Geographic comparison
- Exhibit 27: North America - Market size and forecast 2020-2025 ($ million)
- 7.3 North America - Market size and forecast 2020-2025
- Exhibit 28: North America - Year-over-year growth 2020-2025 (%)
- Exhibit 29: Europe - Market size and forecast 2020-2025 ($ million)
- 7.4 Europe - Market size and forecast 2020-2025
- Exhibit 30: Europe - Year-over-year growth 2020-2025 (%)
- Exhibit 31: Asia - Market size and forecast 2020-2025 ($ million)
- 7.5 Asia - Market size and forecast 2020-2025
- Exhibit 32: Asia - Year-over-year growth 2020-2025 (%)
- Exhibit 33: ROW - Market size and forecast 2020-2025 ($ million)
- 7.6 ROW - Market size and forecast 2020-2025
- Exhibit 34: ROW - Year-over-year growth 2020-2025 (%)
- Exhibit 35: Key leading countries
- 7.7 Key leading countries
- 7.8 Market opportunity by geography
- Exhibit 36: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.2 Market challenges
- Exhibit 37: Impact of drivers and challenges
9 Vendor Landscape
- 9.1 Competitive scenario
- Exhibit 38: Vendor landscape
- 9.2 Vendor landscape
- Exhibit 39: Landscape disruption
- 9.3 Landscape disruption
- Exhibit 40: Industry risks
10 Vendor Analysis
- 10.2 Market positioning of vendors
- Exhibit 42: Market positioning of vendors
- Exhibit 43: AbbVie Inc. - Overview
- Exhibit 44: AbbVie Inc. - Product and service
- Exhibit 45: AbbVie Inc. - Key news
- 10.4 Alliance Pharma Plc
- Exhibit 50: Alliance Pharma Plc - Key offerings
- Exhibit 51: Alliance Pharma Plc - Segment focus
- Exhibit 52: Bausch Health Companies Inc. - Overview
- Exhibit 53: Bausch Health Companies Inc. - Business segments
- 10.5 Bausch Health Companies Inc.
- Exhibit 54: Bausch Health Companies Inc. - Key news
- Exhibit 55: Bausch Health Companies Inc. - Key offerings
- Exhibit 56: Bausch Health Companies Inc. - Segment focus
- Exhibit 57: Bayer AG - Overview
- Exhibit 58: Bayer AG - Business segments
- 10.6 Bayer AG
- Exhibit 59: Bayer AG - Key news
- Exhibit 60: Bayer AG - Key offerings
- Exhibit 61: Bayer AG - Segment focus
- Exhibit 62: Eli Lilly and Co. - Overview
- Exhibit 63: Eli Lilly and Co. - Business segments
- Exhibit 64: Eli Lilly and Co. - Key news
- 10.7 Eli Lilly and Co.
- Exhibit 65: Eli Lilly and Co. - Key offerings
- Exhibit 66: Encore Dermatology Inc. - Overview
- Exhibit 67: Encore Dermatology Inc. - Product and service
- Exhibit 68: Encore Dermatology Inc. - Key offerings
- 10.8 Encore Dermatology Inc.
- Exhibit 69: LEO Pharma AS - Overview
- Exhibit 70: LEO Pharma AS - Business segments
- Exhibit 71: LEO Pharma AS - Key news
- 10.9 LEO Pharma AS
- Exhibit 72: LEO Pharma AS - Key offerings
- Exhibit 73: LEO Pharma AS - Segment focus
- Exhibit 74: Pfizer Inc. - Overview
- Exhibit 75: Pfizer Inc. - Business segments
- Exhibit 76: Pfizer Inc. - Key news
- 10.10 Pfizer Inc.
- Exhibit 77: Pfizer Inc. - Key offerings
- Exhibit 78: Sanofi SA - Overview
- Exhibit 79: Sanofi SA - Business segments
- 10.11 Sanofi SA
- Exhibit 80: Sanofi SA - Key news
- Exhibit 81: Sanofi SA - Key offerings
- Exhibit 82: Sanofi SA - Segment focus
- Exhibit 83: Viatris Inc. - Overview
- Exhibit 84: Viatris Inc. - Business segments
- 10.12 Viatris Inc.
- Exhibit 85: Viatris Inc. - Key news
- Exhibit 86: Viatris Inc. - Key offerings
- Exhibit 87: Viatris Inc. - Segment focus
11 Appendix
- 11.1 Scope of the report
- Exhibit 88: Currency conversion rates for US$
- 11.2 Currency conversion rates for US$
- Exhibit 89: Research Methodology
- 11.3 Research methodology
- Exhibit 90: Validation techniques employed for market sizing
- Exhibit 91: Information sources
- Exhibit 92: List of abbreviations
- 11.4 List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article